Yes, Alzheimer's disease can be treated, but it cannot currently be cured. Approved medicines can manage symptoms, while newer treatments can slow decline in some people with early disease. The practical question is which goal applies: easing symptoms or slowing progression. The National Institute on Aging explains that neither approach reverses existing brain-cell loss or stops the disease completely.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Symptom treatment versus disease-slowing treatment
- Medicines that manage symptoms
- Who may qualify for anti-amyloid treatment?
- Risks and monitoring requirements
- What to ask before making a decision
Symptom treatment versus disease-slowing treatment
Symptom medicines support memory, thinking, or daily function for a limited time. They may help someone remain more independent, but their effects can diminish as Alzheimer's advances. Disease-slowing treatments target beta-amyloid, a protein that forms plaques in the brain.
Removing plaques can modestly delay further decline in selected patients. It does not rebuild lost brain cells or restore previous abilities. These differences matter when judging whether a treatment works. A person may continue to worsen despite receiving an effective disease-slowing medicine; the intended benefit is slower worsening than would otherwise occur.
Medicines that manage symptoms
Donepezil, galantamine, and rivastigmine are cholinesterase inhibitors. They primarily treat cognitive symptoms and may temporarily preserve daily function. Their benefits may become less noticeable as the disease progresses. Memantine also treats cognitive symptoms rather than the underlying disease.
A clinician can consider the person's stage of Alzheimer's, current difficulties, and treatment response when deciding whether a symptom medicine remains useful. Families should set concrete goals before starting or reviewing treatment. Examples include following conversations more easily, completing familiar tasks with less help, or maintaining a daily routine. Tracking those goals gives the clinician better information than asking only whether memory seems "better.".
Who may qualify for anti-amyloid treatment?
Lecanemab, sold as Leqembi, and donanemab, sold as Kisunla, are FDA-approved anti-amyloid infusions. Treatment was studied in people with mild cognitive impairment or mild dementia caused by Alzheimer's, not those with moderate or severe disease. Eligibility also requires confirmed amyloid pathology.
Having memory problems or an Alzheimer's diagnosis alone is therefore insufficient. The benefit is measurable but limited. In FDA-reviewed lecanemab data, participants declined 0.45 points less on the CDR-SB scale than the placebo group over 18 months—a 27% relative reduction, according to the FDA trial summary. Donanemab also significantly reduced clinical decline versus placebo at 76 weeks in its 1,736-patient trial, as described in the FDA approval notice.
Risks and monitoring requirements
Both anti-amyloid medicines can cause amyloid-related imaging abnormalities, known as ARIA. These abnormalities involve brain swelling or bleeding. Serious and life-threatening events can occur. People with two copies of the ApoE ε4 gene have a higher ARIA risk.
Genetic status does not by itself decide treatment, but it makes an individualized risk discussion especially important. Lecanemab requires confirmed amyloid pathology and a baseline MRI. The revised FDA prescribing label also calls for MRIs before the third, fifth, seventh, and fourteenth infusions. This monitoring burden is part of treatment, not an optional precaution.
What to ask before making a decision
Treatment choice depends on disease stage, likely benefit, safety risk, monitoring demands, and access. For eligible Medicare patients, coverage for anti-amyloid antibodies remains tied to CMS Coverage with Evidence Development, including clinician data submission through a qualifying registry.
A prescription alone does not guarantee access. Bring these questions to the treating clinician: If anti-amyloid treatment is unsuitable, symptom treatment may still be appropriate. Ask the clinician to document the treatment goal and set a date to review function, side effects, and whether the medicine remains worthwhile.
- Is the person's condition mild enough to match the patients studied?
- Has amyloid pathology been confirmed?
- What outcome would count as a meaningful benefit?
- What is the person's ARIA risk, including ApoE ε4 status?
- Can the family manage repeated infusions and scheduled MRI monitoring?
